บริษัทใบยาไฟโตฟาร์ม จำกัด
Biopharmaceutical proteins including monoclonal antibodies, vaccine, therapeutic enzymes are the next blockbuster products of pharma industries. Current mammalian cell-based platform have an issue of scalability and time-consuming from research scale to industrial scale production. It is also not versatile to a changing disease trends, outbreaks and pandemic. Even the high investment in research and development of new medicine, only 10% went through Phase I clinical trials were approved by the FDA. Multinational pharmaceutical companies focus on diseases with high prevalence, many patients with some diseases are left with no access to treatment. This market is even though considered as niche however, high value market.
website www.baiyaphytopharm.com